Effect of Candesarutan and Piogritazon in diabetic patients with hypertensio
Not Applicable
Completed
- Conditions
- Diabetic patients with hypertension
- Registration Number
- JPRN-UMIN000010142
- Lead Sponsor
- The jikei University School of Medicin
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Not provided
Exclusion Criteria
Contraindicated of Piogritazon and Candesartan. Informed consent can not be obtained. Patients judged to be unsuitable
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Evaluation of marker for inflammation in diabetic patients with hypertension
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie the antihypertensive effects of candesartan in diabetic patients?
How does pioglitazone compare to other thiazolidinediones in managing hypertension among type 2 diabetes patients?
Which biomarkers correlate with improved blood pressure outcomes in diabetic hypertensive patients treated with candesartan and pioglitazone?
What are the potential adverse events associated with candesartan and pioglitazone combination therapy in diabetic patients?
Are there alternative drug combinations to candesartan and pioglitazone for treating hypertension in diabetic populations?